Back to trial details

Intake questionnaire

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Applying to University of Alabama at Birmingham Cancer Center · Birmingham, Alabama

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Anatomic Stage II Breast Cancer AJCC v8?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Birmingham for study visits?